Emerging research shows there are ‘super-responders’ to GLP-1 drugs, and others who don’t respond at all.
Richard Isaacson is a neurologist who works with patients who are trying to prevent Alzheimers disease. Hes also a patient experimenting with his own doctor to see if tiny doses of a GLP-1 medication… [+412 chars]